Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aptorum Group Ltd Cl A (APM)

Aptorum Group Ltd Cl A (APM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,426
  • Shares Outstanding, K 6,347
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,270 K
  • EBIT $ 0 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0705 +6.49%
on 12/17/25
1.4400 -20.83%
on 12/05/25
-0.2000 (-14.93%)
since 11/26/25
3-Month
1.0705 +6.49%
on 12/17/25
2.5899 -55.98%
on 10/08/25
-0.7100 (-38.38%)
since 09/26/25
52-Week
0.6900 +65.22%
on 04/07/25
7.4899 -84.78%
on 12/31/24
+0.2799 (+32.54%)
since 12/26/24

Most Recent Stories

More News
Aptorum Group Announces Merger with DiamiR Biosciences

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

APM : 1.1400 (-2.56%)
Aptorum Group Announces Strategic Merger with DiamiR Biosciences

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aptorum Group...

APM : 1.1400 (-2.56%)
Aptorum Group Releases Interim Financial Results for June 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aptorum Group...

APM : 1.1400 (-2.56%)
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency

Regulatory News:

APM : 1.1400 (-2.56%)
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited

Regulatory News:

APM : 1.1400 (-2.56%)
Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Regulatory News:

APM : 1.1400 (-2.56%)
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Regulatory News:

APM : 1.1400 (-2.56%)
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Regulatory News:

APM : 1.1400 (-2.56%)
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Regulatory News:

APM : 1.1400 (-2.56%)
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Regulatory News:

APM : 1.1400 (-2.56%)

Business Summary

Aptorum Group Limited is a pharmaceutical company. It engaged in developing and commercializing therapeutic and diagnostic technologies to tackle unmet medical needs. The company's therapeutic and diagnostic project primarily includes neurology, infectious diseases, gastroenterology, oncology and other...

See More

Key Turning Points

3rd Resistance Point 1.2367
2nd Resistance Point 1.2133
1st Resistance Point 1.1767
Last Price 1.1400
1st Support Level 1.1167
2nd Support Level 1.0933
3rd Support Level 1.0567

See More

52-Week High 7.4899
Fibonacci 61.8% 4.8923
Fibonacci 50% 4.0900
Fibonacci 38.2% 3.2876
Last Price 1.1400
52-Week Low 0.6900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar